Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Currently, there is only one U.S. government-approved treatment available for fatty liver disease, Rezdiffra (resmetirom), ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy.

Novo Nordisk (NVO) on Tuesday announced that it is enabling select telehealth providers to offer Wegovy, expanding access to ...